Precision BioSciences (DTIL) Competitors

$7.37 -0.08 (-1.07%)

As of 09/3/2026 04:00 PM Eastern

DTIL vs. ACRS, CTMX, FDMT, MNPR, and PHAR

Should you buy Precision BioSciences stock or one of its competitors? Precision BioSciences's main competitors and comparable companies include Aclaris Therapeutics (ACRS), CytomX Therapeutics (CTMX), 4D Molecular Therapeutics (FDMT), Monopar Therapeutics (MNPR), and Pharming Group (PHAR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Precision BioSciences compare to Aclaris Therapeutics?

Precision BioSciences (NASDAQ:DTIL) and Aclaris Therapeutics (NASDAQ:ACRS) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, earnings, profitability and media sentiment.

38.0% of Precision BioSciences shares are held by institutional investors. Comparatively, 98.3% of Aclaris Therapeutics shares are held by institutional investors. 2.7% of Precision BioSciences shares are held by insiders. Comparatively, 4.8% of Aclaris Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Precision BioSciences presently has a consensus target price of $32.25, indicating a potential upside of 337.58%. Aclaris Therapeutics has a consensus target price of $11.33, indicating a potential upside of 90.48%. Given Precision BioSciences' higher possible upside, equities analysts clearly believe Precision BioSciences is more favorable than Aclaris Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Precision BioSciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Aclaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	3 Strong Buy rating(s)	3.11

Precision BioSciences has higher revenue and earnings than Aclaris Therapeutics. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than Precision BioSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Precision BioSciences	$34.26M	5.94	-$45.72M	-$2.80	N/A
Aclaris Therapeutics	$7.83M	106.25	-$64.92M	-$0.58	N/A

Precision BioSciences has a beta of 1.24, indicating that its share price is 24% more volatile than the broader market. Comparatively, Aclaris Therapeutics has a beta of 0.79, indicating that its share price is 21% less volatile than the broader market.

Precision BioSciences has a net margin of -96.73% compared to Aclaris Therapeutics' net margin of -921.50%. Aclaris Therapeutics' return on equity of -61.65% beat Precision BioSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Precision BioSciences	-96.73%	-72.52%	-32.25%
Aclaris Therapeutics	-921.50%	-61.65%	-42.41%

In the previous week, Aclaris Therapeutics had 8 more articles in the media than Precision BioSciences. MarketBeat recorded 8 mentions for Aclaris Therapeutics and 0 mentions for Precision BioSciences. Aclaris Therapeutics' average media sentiment score of 1.01 beat Precision BioSciences' score of 0.00 indicating that Aclaris Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Precision BioSciences	Neutral
Aclaris Therapeutics	Positive

Summary

Aclaris Therapeutics beats Precision BioSciences on 10 of the 17 factors compared between the two stocks.

How does Precision BioSciences compare to CytomX Therapeutics?

CytomX Therapeutics (NASDAQ:CTMX) and Precision BioSciences (NASDAQ:DTIL) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, risk, profitability, dividends, media sentiment and valuation.

In the previous week, CytomX Therapeutics had 5 more articles in the media than Precision BioSciences. MarketBeat recorded 5 mentions for CytomX Therapeutics and 0 mentions for Precision BioSciences. CytomX Therapeutics' average media sentiment score of 0.72 beat Precision BioSciences' score of 0.00 indicating that CytomX Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
CytomX Therapeutics	Positive
Precision BioSciences	Neutral

CytomX Therapeutics presently has a consensus price target of $11.90, indicating a potential upside of 223.37%. Precision BioSciences has a consensus price target of $32.25, indicating a potential upside of 337.58%. Given Precision BioSciences' higher possible upside, analysts plainly believe Precision BioSciences is more favorable than CytomX Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CytomX Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83
Precision BioSciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

CytomX Therapeutics has higher revenue and earnings than Precision BioSciences. CytomX Therapeutics is trading at a lower price-to-earnings ratio than Precision BioSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CytomX Therapeutics	$76.20M	10.52	-$17.37M	-$0.50	N/A
Precision BioSciences	$34.26M	5.94	-$45.72M	-$2.80	N/A

CytomX Therapeutics has a beta of 2.14, meaning that its share price is 114% more volatile than the broader market. Comparatively, Precision BioSciences has a beta of 1.24, meaning that its share price is 24% more volatile than the broader market.

67.8% of CytomX Therapeutics shares are owned by institutional investors. Comparatively, 38.0% of Precision BioSciences shares are owned by institutional investors. 3.8% of CytomX Therapeutics shares are owned by company insiders. Comparatively, 2.7% of Precision BioSciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Precision BioSciences has a net margin of -96.73% compared to CytomX Therapeutics' net margin of -435.21%. CytomX Therapeutics' return on equity of -38.46% beat Precision BioSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CytomX Therapeutics	-435.21%	-38.46%	-30.33%
Precision BioSciences	-96.73%	-72.52%	-32.25%

Summary

CytomX Therapeutics beats Precision BioSciences on 14 of the 17 factors compared between the two stocks.

How does Precision BioSciences compare to 4D Molecular Therapeutics?

Precision BioSciences (NASDAQ:DTIL) and 4D Molecular Therapeutics (NASDAQ:FDMT) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, media sentiment, earnings, dividends and institutional ownership.

Precision BioSciences has a beta of 1.24, suggesting that its share price is 24% more volatile than the broader market. Comparatively, 4D Molecular Therapeutics has a beta of 2.74, suggesting that its share price is 174% more volatile than the broader market.

Precision BioSciences has higher earnings, but lower revenue than 4D Molecular Therapeutics. 4D Molecular Therapeutics is trading at a lower price-to-earnings ratio than Precision BioSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Precision BioSciences	$34.26M	5.94	-$45.72M	-$2.80	N/A
4D Molecular Therapeutics	$85.21M	9.53	-$140.11M	-$2.63	N/A

38.0% of Precision BioSciences shares are held by institutional investors. Comparatively, 99.3% of 4D Molecular Therapeutics shares are held by institutional investors. 2.7% of Precision BioSciences shares are held by company insiders. Comparatively, 7.9% of 4D Molecular Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, 4D Molecular Therapeutics had 4 more articles in the media than Precision BioSciences. MarketBeat recorded 4 mentions for 4D Molecular Therapeutics and 0 mentions for Precision BioSciences. 4D Molecular Therapeutics' average media sentiment score of 1.12 beat Precision BioSciences' score of 0.00 indicating that 4D Molecular Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Precision BioSciences	Neutral
4D Molecular Therapeutics	Positive

Precision BioSciences has a net margin of -96.73% compared to 4D Molecular Therapeutics' net margin of -194.74%. 4D Molecular Therapeutics' return on equity of -41.33% beat Precision BioSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Precision BioSciences	-96.73%	-72.52%	-32.25%
4D Molecular Therapeutics	-194.74%	-41.33%	-35.90%

Precision BioSciences presently has a consensus target price of $32.25, suggesting a potential upside of 337.58%. 4D Molecular Therapeutics has a consensus target price of $29.63, suggesting a potential upside of 101.53%. Given Precision BioSciences' higher probable upside, equities analysts plainly believe Precision BioSciences is more favorable than 4D Molecular Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Precision BioSciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
4D Molecular Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

Summary

4D Molecular Therapeutics beats Precision BioSciences on 12 of the 17 factors compared between the two stocks.

How does Precision BioSciences compare to Monopar Therapeutics?

Precision BioSciences (NASDAQ:DTIL) and Monopar Therapeutics (NASDAQ:MNPR) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, valuation, institutional ownership, dividends, analyst recommendations and profitability.

Precision BioSciences presently has a consensus target price of $32.25, indicating a potential upside of 337.58%. Monopar Therapeutics has a consensus target price of $118.67, indicating a potential upside of 0.10%. Given Precision BioSciences' higher probable upside, equities analysts clearly believe Precision BioSciences is more favorable than Monopar Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Precision BioSciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Monopar Therapeutics	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86

Precision BioSciences has a beta of 1.24, meaning that its share price is 24% more volatile than the broader market. Comparatively, Monopar Therapeutics has a beta of 1.49, meaning that its share price is 49% more volatile than the broader market.

Monopar Therapeutics has lower revenue, but higher earnings than Precision BioSciences. Monopar Therapeutics is trading at a lower price-to-earnings ratio than Precision BioSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Precision BioSciences	$34.26M	5.94	-$45.72M	-$2.80	N/A
Monopar Therapeutics	N/A	N/A	-$13.72M	-$2.17	N/A

38.0% of Precision BioSciences shares are held by institutional investors. Comparatively, 1.8% of Monopar Therapeutics shares are held by institutional investors. 2.7% of Precision BioSciences shares are held by insiders. Comparatively, 9.7% of Monopar Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Monopar Therapeutics had 3 more articles in the media than Precision BioSciences. MarketBeat recorded 3 mentions for Monopar Therapeutics and 0 mentions for Precision BioSciences. Monopar Therapeutics' average media sentiment score of 0.54 beat Precision BioSciences' score of 0.00 indicating that Monopar Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Precision BioSciences	Neutral
Monopar Therapeutics	Positive

Monopar Therapeutics has a net margin of 0.00% compared to Precision BioSciences' net margin of -96.73%. Monopar Therapeutics' return on equity of -13.08% beat Precision BioSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Precision BioSciences	-96.73%	-72.52%	-32.25%
Monopar Therapeutics	N/A	-13.08%	-12.79%

Summary

Monopar Therapeutics beats Precision BioSciences on 12 of the 16 factors compared between the two stocks.

How does Precision BioSciences compare to Pharming Group?

Precision BioSciences (NASDAQ:DTIL) and Pharming Group (NASDAQ:PHAR) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, earnings, institutional ownership, analyst recommendations, valuation, profitability, risk and media sentiment.

Pharming Group has higher revenue and earnings than Precision BioSciences. Precision BioSciences is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Precision BioSciences	$34.26M	5.94	-$45.72M	-$2.80	N/A
Pharming Group	$376.13M	2.16	$2.85M	$0.12	95.50

Precision BioSciences has a beta of 1.24, indicating that its share price is 24% more volatile than the broader market. Comparatively, Pharming Group has a beta of 0.01, indicating that its share price is 99% less volatile than the broader market.

In the previous week, Pharming Group had 1 more articles in the media than Precision BioSciences. MarketBeat recorded 1 mentions for Pharming Group and 0 mentions for Precision BioSciences. Pharming Group's average media sentiment score of 1.55 beat Precision BioSciences' score of 0.00 indicating that Pharming Group is being referred to more favorably in the news media.

Company	Overall Sentiment
Precision BioSciences	Neutral
Pharming Group	Very Positive

Pharming Group has a net margin of 2.51% compared to Precision BioSciences' net margin of -96.73%. Pharming Group's return on equity of 3.40% beat Precision BioSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Precision BioSciences	-96.73%	-72.52%	-32.25%
Pharming Group	2.51%	3.40%	1.90%

Precision BioSciences currently has a consensus price target of $32.25, indicating a potential upside of 337.58%. Pharming Group has a consensus price target of $38.67, indicating a potential upside of 237.41%. Given Precision BioSciences' stronger consensus rating and higher possible upside, equities research analysts plainly believe Precision BioSciences is more favorable than Pharming Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Precision BioSciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Pharming Group	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

38.0% of Precision BioSciences shares are held by institutional investors. Comparatively, 0.0% of Pharming Group shares are held by institutional investors. 2.7% of Precision BioSciences shares are held by company insiders. Comparatively, 2.1% of Pharming Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Pharming Group beats Precision BioSciences on 9 of the 16 factors compared between the two stocks.

Get Precision BioSciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DTIL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DTIL vs. The Competition

Export

Metric	Precision BioSciences	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$205.63M	$4.03B	$7.26B	$12.73B
Dividend Yield	N/A	3.60%	2.53%	8.86%
P/E Ratio	-2.63	12.66	273.29	25.38
Price / Sales	5.94	1,309.08	613.45	97.56
Price / Cash	N/A	106.87	77.82	52.26
Price / Book	4.49	16.29	12.89	6.14
Net Income	-$45.72M	-$22.72M	$3.47B	$349.01M
7 Day Performance	-5.27%	0.34%	0.60%	-0.27%
1 Month Performance	1.24%	8.52%	5.73%	0.68%
1 Year Performance	46.52%	52.66%	25.35%	14.84%

Precision BioSciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DTIL Precision BioSciences	2.4289 of 5 stars	$7.37 -1.1%	$32.25 +337.6%	+45.9%	$205.63M	$34.26M	N/A	200
ACRS Aclaris Therapeutics	2.5461 of 5 stars	$6.02 -0.5%	$11.33 +88.3%	+188.8%	$841.72M	$7.83M	N/A	100	News Coverage Analyst Forecast
CTMX CytomX Therapeutics	2.5525 of 5 stars	$3.67 +9.2%	$11.90 +224.3%	+73.6%	$799.69M	$76.20M	N/A	170
FDMT 4D Molecular Therapeutics	2.7124 of 5 stars	$14.35 +1.7%	$29.63 +106.4%	+127.2%	$792.69M	$85.21M	N/A	120	Positive News
MNPR Monopar Therapeutics	1.628 of 5 stars	$117.57 +5.0%	$118.67 +0.9%	+227.4%	$788.90M	N/A	N/A	10

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DTIL) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Precision BioSciences (DTIL) Competitors

DTIL vs. ACRS, CTMX, FDMT, MNPR, and PHAR

How does Precision BioSciences compare to Aclaris Therapeutics?

Summary

How does Precision BioSciences compare to CytomX Therapeutics?

Summary

How does Precision BioSciences compare to 4D Molecular Therapeutics?

Summary

How does Precision BioSciences compare to Monopar Therapeutics?

Summary

How does Precision BioSciences compare to Pharming Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DTIL vs. The Competition

Precision BioSciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Precision BioSciences (DTIL) Competitors

DTIL vs. ACRS, CTMX, FDMT, MNPR, and PHAR

How does Precision BioSciences compare to Aclaris Therapeutics?

Do institutionals and insiders believe in DTIL or ACRS?

Do analysts prefer DTIL or ACRS?

Which has higher valuation and earnings, DTIL or ACRS?

Which has more risk and volatility, DTIL or ACRS?

Is DTIL or ACRS more profitable?

Does the media favor DTIL or ACRS?

Summary

How does Precision BioSciences compare to CytomX Therapeutics?

Does the media refer more to CTMX or DTIL?

Do analysts recommend CTMX or DTIL?

Which has stronger valuation and earnings, CTMX or DTIL?

Which has more volatility & risk, CTMX or DTIL?

Do insiders and institutionals have more ownership in CTMX or DTIL?

Is CTMX or DTIL more profitable?

Summary

How does Precision BioSciences compare to 4D Molecular Therapeutics?

Which has more risk & volatility, DTIL or FDMT?

Which has higher earnings and valuation, DTIL or FDMT?

Do institutionals & insiders have more ownership in DTIL or FDMT?

Does the media prefer DTIL or FDMT?

Is DTIL or FDMT more profitable?

Do analysts prefer DTIL or FDMT?

Summary

How does Precision BioSciences compare to Monopar Therapeutics?

Do analysts recommend DTIL or MNPR?

Which has more risk & volatility, DTIL or MNPR?

Which has preferable valuation and earnings, DTIL or MNPR?

Do insiders and institutionals believe in DTIL or MNPR?

Does the media prefer DTIL or MNPR?

Is DTIL or MNPR more profitable?

Summary

How does Precision BioSciences compare to Pharming Group?

Which has stronger valuation & earnings, DTIL or PHAR?

Which has more risk and volatility, DTIL or PHAR?

Does the media prefer DTIL or PHAR?

Is DTIL or PHAR more profitable?

Do analysts recommend DTIL or PHAR?

Do institutionals & insiders believe in DTIL or PHAR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DTIL vs. The Competition

Precision BioSciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools